Share on

Europe Oncology Drugs Market Research Report – Segmented By Type, Drug Class, Distribution Channel, Route Of Administration, Drug Classification & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 12280
Pages: 125
Formats: report pdf report excel report power bi report ppt

Europe Oncology Drugs Market Size (2022 to 2027)

The market size for oncology drugs in the European region was worth USD 50.64 billion in 2022 and is forecasted to value USD 75.11 billion by 2027, growing at a CAGR of 8.20% from 2022 to 2027.

Oncology helps study, diagnosis, and treatment of cancer. Cancer is a disease where abnormal cells grow uncontrollably and disrupt normal bodily functions. Oncology drugs act against both metastatic and benign cancers, including bone marrow cancer, lung cancer, bone cancer, skin cancer, gastrointestinal cancer, breast cancer, oral cancer, gynecological cancer, etc. 

The need for cancer treatments develops in tandem with the number of cancer diagnoses and deaths. Targeted therapy is becoming more popular as a cancer treatment. They offer several advantages over conventional therapies like chemotherapy and radiation. The many types of cancer medicines available are shown through a detailed market analysis by product category. Additionally, medical research has received much attention to reducing cancer incidence. As healthcare prices rise in different world regions, the market is growing. As a result, the European oncology drugs market has been propelled forward by rising cancer incidence. Cutting-edge cancer treatment technologies and techniques, as well as rising healthcare spending in developing nations, are likely to boost the European oncology drugs market forward. 

Moreover, regional pharmaceutical companies developing generic cancer treatments have formed strategic alliances to focus their efforts on developing high-efficacy generic oncology medicines. These strategic decisions have paid off handsomely for these companies, allowing them to retain market dominance in generic cancer medicines.

However, Chemotherapy medications attack cancer cells and kill healthy cells in the body, resulting in a myriad of negative side effects for patients. Bone marrow suppression, gastrointestinal disorders, neuropathies, hair loss, weariness, and skin ailments are the most common side effects. As a result, the market's expansion is constrained by cancer treatments' undesirable side effects.

Other factors limiting European oncology drugs market expansion during the forecast period are stringent government regulations, high medical costs, and patient expiration. In most affluent countries, medical technology evaluation is becoming more common. Price management is crucial in the oncology drugs market and frequently employs financial risk-sharing agreements. The cost discrepancies between brand-name and generic medications are being investigated. Global studies are increasing patient enrolment to improve the local relevance of trials in European regulatory processes and shorten the time to market. According to manufacturers, internal product development activities should be integrated from the start.

This research report on the Europe oncology drugs market has been segmented and sub-segmented into the following categories:

By Type:

  • Lung Cancer
  • Pancreatic Cancer
  • Breast Cancer
  • Prostate Cancer
  • Ovarian Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Kidney Cancer
  • Brain Cancer
  • Thyroid Cancer
  • Skin Cancer
  • Bladder Cancer
  • Cervical Cancer
  • Blood Cancer
  • Others

By Drug Class Type:

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies/Drug Stores
  • Others

By Route of Administration:

  • Oral
  • Parenteral
  • Others

By Drug Classification:

  • Branded Drugs
  • Generic Drugs

By Country:

  • United Kingdom
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands and
  • Rest of Europe

Geographically, the European oncology drugs market is projected to account for a predominant share in the global market during the forecast period. Numerous multi-national organizations support cancer drugs, and the government increased a healthcare investment. However, Pharmaceutical treatments for cancer are becoming more effective. Countries like Spain and France play a key role in oncology medication discovery and infrastructure development. In major countries, such as Germany, the United Kingdom, and Italy, lung cancer is the most common drug usage, whereas prostate cancer is the most common.  Spain and France have the largest geographical market share for cancer oncology medications. In the cancer oncology market, Spain and France have a major presence.

The German oncology drugs market dominated the European market, and it is anticipated to continue its dominance during the forecast period. The well-established healthcare infrastructure, increasing disposable income, and supportive government policies propel market growth. Other factors, such as cervical and liver cancers, are more frequent. Germany plays an important part in the procurement of anticancer prescription therapies in the region.


F. Hoffmann-La Roche Ltd, Genentech, Inc., Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca, Sanofi, and Bayer AG are some of the notable companies in the European oncology drugs market.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample